Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies

Scott Kahan; Katherine H. Saunders; Lee M. Kaplan

doi:10.1016/j.tige.2020.05.002

Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies

Scott Kahan, Katherine H. Saunders, Lee M. Kaplan

Bloomberg School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

Endoscopic bariatric and metabolic therapies (EBMT) are rarely used in the United States. Compared with EBMTs alone, combining EBMTs with obesity pharmacotherapy may increase the magnitude and durability of weight loss and ultimately may contribute to increased patient satisfaction and EBMT utilization. Though combination therapy is frequently used in clinical practice, few published studies of combination EBMT/pharmacotherapy are available. Available studies and abstracts suggest that combination strategies are promising, but further research and clinical trials are needed. This article will review available obesity pharmacotherapy options and describe current data on combining EBMT and pharmacotherapy.

Original language	English (US)
Pages (from-to)	154-158
Number of pages	5
Journal	Techniques and Innovations in Gastrointestinal Endoscopy
Volume	22
Issue number	3
DOIs	https://doi.org/10.1016/j.tige.2020.05.002
State	Published - Jul 2020

ASJC Scopus subject areas

Gastroenterology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.tige.2020.05.002

Cite this

@article{35911a1c0c9847c0af9937778b6f2792,

title = "Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies",

abstract = "Endoscopic bariatric and metabolic therapies (EBMT) are rarely used in the United States. Compared with EBMTs alone, combining EBMTs with obesity pharmacotherapy may increase the magnitude and durability of weight loss and ultimately may contribute to increased patient satisfaction and EBMT utilization. Though combination therapy is frequently used in clinical practice, few published studies of combination EBMT/pharmacotherapy are available. Available studies and abstracts suggest that combination strategies are promising, but further research and clinical trials are needed. This article will review available obesity pharmacotherapy options and describe current data on combining EBMT and pharmacotherapy.",

author = "Scott Kahan and Saunders, {Katherine H.} and Kaplan, {Lee M.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

doi = "10.1016/j.tige.2020.05.002",

language = "English (US)",

volume = "22",

pages = "154--158",

journal = "Techniques and Innovations in Gastrointestinal Endoscopy",

issn = "2666-5107",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies

AU - Kahan, Scott

AU - Saunders, Katherine H.

AU - Kaplan, Lee M.

PY - 2020/7

Y1 - 2020/7

N2 - Endoscopic bariatric and metabolic therapies (EBMT) are rarely used in the United States. Compared with EBMTs alone, combining EBMTs with obesity pharmacotherapy may increase the magnitude and durability of weight loss and ultimately may contribute to increased patient satisfaction and EBMT utilization. Though combination therapy is frequently used in clinical practice, few published studies of combination EBMT/pharmacotherapy are available. Available studies and abstracts suggest that combination strategies are promising, but further research and clinical trials are needed. This article will review available obesity pharmacotherapy options and describe current data on combining EBMT and pharmacotherapy.

AB - Endoscopic bariatric and metabolic therapies (EBMT) are rarely used in the United States. Compared with EBMTs alone, combining EBMTs with obesity pharmacotherapy may increase the magnitude and durability of weight loss and ultimately may contribute to increased patient satisfaction and EBMT utilization. Though combination therapy is frequently used in clinical practice, few published studies of combination EBMT/pharmacotherapy are available. Available studies and abstracts suggest that combination strategies are promising, but further research and clinical trials are needed. This article will review available obesity pharmacotherapy options and describe current data on combining EBMT and pharmacotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85100831598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100831598&partnerID=8YFLogxK

U2 - 10.1016/j.tige.2020.05.002

DO - 10.1016/j.tige.2020.05.002

M3 - Review article

AN - SCOPUS:85100831598

SN - 2666-5107

VL - 22

SP - 154

EP - 158

JO - Techniques and Innovations in Gastrointestinal Endoscopy

JF - Techniques and Innovations in Gastrointestinal Endoscopy

IS - 3

ER -

Combining obesity pharmacotherapy with endoscopic bariatric and metabolic therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this